178 related articles for article (PubMed ID: 32012858)
1. uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines.
Biagioni A; Laurenzana A; Chillà A; Del Rosso M; Andreucci E; Poteti M; Bani D; Guasti D; Fibbi G; Margheri F
Cells; 2020 Jan; 9(2):. PubMed ID: 32012858
[TBL] [Abstract][Full Text] [Related]
2. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
3. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma.
Semina EV; Rubina KA; Shmakova AA; Rysenkova KD; Klimovich PS; Aleksanrushkina NA; Sysoeva VY; Karagyaur MN; Tkachuk VA
J Cell Physiol; 2020 Sep; 235(9):6268-6286. PubMed ID: 31990070
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.
Biagioni A; Chillà A; Del Rosso M; Fibbi G; Scavone F; Andreucci E; Peppicelli S; Bianchini F; Calorini L; Li Santi A; Ragno P; Margheri F; Laurenzana A
Front Oncol; 2021; 11():663225. PubMed ID: 34055629
[TBL] [Abstract][Full Text] [Related]
6. uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.
Laurenzana A; Chillà A; Luciani C; Peppicelli S; Biagioni A; Bianchini F; Tenedini E; Torre E; Mocali A; Calorini L; Margheri F; Fibbi G; Del Rosso M
Int J Cancer; 2017 Sep; 141(6):1190-1200. PubMed ID: 28577299
[TBL] [Abstract][Full Text] [Related]
7. Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolism.
Ždralević M; Brand A; Di Ianni L; Dettmer K; Reinders J; Singer K; Peter K; Schnell A; Bruss C; Decking SM; Koehl G; Felipe-Abrio B; Durivault J; Bayer P; Evangelista M; O'Brien T; Oefner PJ; Renner K; Pouysségur J; Kreutz M
J Biol Chem; 2018 Oct; 293(41):15947-15961. PubMed ID: 30158244
[TBL] [Abstract][Full Text] [Related]
8. uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells.
Biagioni A; Laurenzana A; Menicacci B; Peppicelli S; Andreucci E; Bianchini F; Guasti D; Paoli P; Serratì S; Mocali A; Calorini L; Del Rosso M; Fibbi G; Chillà A; Margheri F
Cell Mol Life Sci; 2021 Mar; 78(6):3057-3072. PubMed ID: 33237352
[TBL] [Abstract][Full Text] [Related]
9. Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase.
Mazzio E; Badisa R; Mack N; Cassim S; Zdralevic M; Pouyssegur J; Soliman KFA
Cancer Genomics Proteomics; 2020; 17(5):469-497. PubMed ID: 32859627
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
van Veen M; Matas-Rico E; van de Wetering K; Leyton-Puig D; Kedziora KM; De Lorenzi V; Stijf-Bultsma Y; van den Broek B; Jalink K; Sidenius N; Perrakis A; Moolenaar WH
Elife; 2017 Aug; 6():. PubMed ID: 28849762
[TBL] [Abstract][Full Text] [Related]
11. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
[TBL] [Abstract][Full Text] [Related]
12. Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter.
Teimoori-Toolabi L; Azadmanesh K; Amanzadeh A; Zeinali S
BioDrugs; 2010 Apr; 24(2):131-46. PubMed ID: 20199127
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.
Liu X; Qiu F; Liu Z; Lan Y; Wang K; Zhou PK; Wang Y; Hua ZC
Apoptosis; 2014 Oct; 19(10):1532-44. PubMed ID: 25113506
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Ahmed N; Oliva K; Wang Y; Quinn M; Rice G
Br J Cancer; 2003 Jul; 89(2):374-84. PubMed ID: 12865932
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
16. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
[TBL] [Abstract][Full Text] [Related]
17. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.
Margheri F; Luciani C; Taddei ML; Giannoni E; Laurenzana A; Biagioni A; Chillà A; Chiarugi P; Fibbi G; Del Rosso M
Oncotarget; 2014 Mar; 5(6):1538-53. PubMed ID: 24681666
[TBL] [Abstract][Full Text] [Related]
18. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
19. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells.
Cavallo-Medved D; Mai J; Dosescu J; Sameni M; Sloane BF
J Cell Sci; 2005 Apr; 118(Pt 7):1493-503. PubMed ID: 15769846
[TBL] [Abstract][Full Text] [Related]
20. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
